1 reports of this reaction
2.1% of all LIDOCAINE HCI reports
#9 most reported adverse reaction
ALOPECIA is the #9 most commonly reported adverse reaction for LIDOCAINE HCI, manufactured by Aurobindo Pharma Limited. There are 1 FDA adverse event reports linking LIDOCAINE HCI to ALOPECIA. This represents approximately 2.1% of all 47 adverse event reports for this drug.
Patients taking LIDOCAINE HCI who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for LIDOCAINE HCI, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for LIDOCAINE HCI:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 1 FDA reports for LIDOCAINE HCI. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 2.1% of all adverse event reports for LIDOCAINE HCI, making it a notable side effect.
If you experience alopecia while taking LIDOCAINE HCI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.